Clinical Trials Logo

Diabetic Retinopathy clinical trials

View clinical trials related to Diabetic Retinopathy.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT03903042 Enrolling by invitation - Clinical trials for Diabetic Retinopathy

Comparison of Aurora Fundus Camera With Traditional Camera in Diabetic Retinopathy With Visual Artificial Intelligence

Start date: November 1, 2018
Phase:
Study type: Observational

This study aims to compare the effect of Aurora handheld fundus camera with traditional desktop fundus camera in the fundus photography screening of diabetic patients, and to evaluate the effect of artificial intelligence algorithm in the diagnosis of diabetic retinopathy.

NCT ID: NCT03665090 Enrolling by invitation - Clinical trials for Diabetic Retinopathy Visually Threatening

Shanghai Cohort Study of Diabetic Eye Disease

SCODE
Start date: January 1, 2016
Phase:
Study type: Observational

To describe the design, methodology and baseline characteristics of the Shanghai Cohort study of Diabetic Eye disease (SCODE) study, a community-based study to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.

NCT ID: NCT03076697 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Smartphone Screening for Eye Diseases

Start date: April 16, 2015
Phase:
Study type: Observational

To validate new screening instruments for eye disease, increase eye care access in underserved communities, and provide a scientifically implemented method to set up programs for eye disease screening.

NCT ID: NCT02911311 Enrolling by invitation - Clinical trials for Proliferative Diabetic Retinopathy

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

Start date: October 12, 2019
Phase: N/A
Study type: Interventional

Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse effects on visual function. Intravitreal injection of vascular endothelial growth factor(VEGF) can induce short-term regression of retinal neovascularization(NV). The purpose is to assess and compare the efficacy and safety between intravitreal injection of conbercept and PRP.

NCT ID: NCT02063321 Enrolling by invitation - Clinical trials for Diabetic Retinopathy

Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic

Start date: December 2012
Phase: N/A
Study type: Observational

The aim of the study is to find out prevalence of diabetic macular edema (DME) in patients with diabetes mellitus in Slovak Republic.The outcome of the project will be epidemiology survey, prevalence of wet form of Diabetic Macular Edema in relation to duration of diabetes, type of diabetes, treatment (insulin vs. OAD or combination) etc. and identification of prognostic factors leading to development of DME.

NCT ID: NCT01382498 Enrolling by invitation - Clinical trials for Diabetic Retinopathy

Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy

Start date: November 2009
Phase: Phase 4
Study type: Interventional

Diabetic retinopathy (DR) is a highly specific vascular complication of type 1 and type 2 diabetes mellitus. Calcium dobesilate(CD) or Doxium has been tested in the treatment of diabetic retinopathy showing a slowdown of the progression of the disease after long-term oral treatment,as a potent antioxidant. Endothelin-1 (ET-1) Besides being a very potent vasoconstrictor,acts as a mitogen on the vascular smooth muscle and play the main role in the failure of autoregulation that it is an important and often early feature of diabetic retinopathy.several studies have been confirmed that inflammation besides oxidative stress are the main mechanisms,in the pathogenesis of DR and hsCRP can play a sensitive role in detecting inflammation in these patients. The aim of this study was to determine the effects of CD on decreasing ET-1 and hsCRP serum levels in patients with diabetic retinopathy.

NCT ID: NCT00703235 Enrolling by invitation - Clinical trials for Diabetic Retinopathy

Intravitreal Bevacizumab for Diabetic Macular Edema

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.